CliffBio
biologic

Alburx

Albumin (Human)

Loss of exclusivityJuly 1988projected — 12-year biologic exclusivity estimate
CompanyCSL Behring →See this company's full patent-cliff portfolio

Drug detail

Brand nameAlburx
Active ingredientAlbumin (Human)
Strength25G/100mL
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJuly 1976
Marketing statusRx

More from CSL Behring

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Alburx patent cliff — loss of exclusivity July 1988 | CliffBio